We may include adverts from us and 3rd parties based on our understanding. After more than 15 years of research, scientists at Princeton University in the US have published two papers describing their promising new therapy. The researchers focused on identifying a little-known but deadly gene called metadherin MTDF, which is present in most major cancer types. Metadherin is present in lung, colon, breast, prostate, and liver cancers, making it a potential target for future cure development.
Cancer biologist Yibin Kang says the Princeton researchers have figured out a way in which this gene can be attacked or disabled. Their research shows that this can be done without any obvious side effects. Professor Kang said: You can't find a better drug target than this: MTDF can be eliminated with no obvious side effects for most major human cancers, not important for normal cells. The new treatment has only been tested on mice and human tissue. The researchers are positive that they will move onto clinical patient trials in a few years. READ MORE: Russia threatens to CUT EU energy as Gazprom's profits soar.
The EU take on China's hydrogen war in the third world Their findings were published in Nature Cancer this week. Professor Kang said in the two papers that we are publishing back-to-back today, we identify a compound, show it is effective against cancer, and show that it is very effective when combined with chemotherapy and immunotherapy. Even though metastatic cancers are scary, by figuring out how they work - figuring out their dependency on certain key pathways like MTDF - we can attack them and make them susceptible to treatment. Over the years, the expert's research focused on cancer metastasis. Metastasis is cancer's ability to spread from one part of the body to another, making the disease more likely to kill.
99 percent of cancer patients survive within five years of receiving their diagnosis, according to data from the National Cancer Institute in the US. Only 29 percent of patients survive if their cancer has metastasised. The study lead author and associate researcher Minhong Shen said that metastatic breast cancer causes more than 40,000 deaths every year in the US, and patients do not respond well to standard treatments, such as chemotherapies, targeted therapies and immunotherapies. Our work identified a series of chemical compounds that could enhance the response rates of chemotherapy and immunotherapy in metastatic breast cancer mouse models. How to live longer: Three food and drink effects on longevity REPORT Cancer: The intermittent warning sign that may occur at night LATEST Cancer: The fleeting symptom that requires urgent investigation INSIGHT AstraZeneca breakthrough INSIGHT AstraZeneca - professor Kang and his colleagues, MTDH allows cancer tumours to survive the stress associated with chemotherapy and muzzles the alarm cry of organs invaded by a tumour. The team developed a new treatment that reactivates the body's alarm system. Professor Kang said that healthy cells in normal tissues are usually not under stress or presenting signals that can be recognized as foreign by the immune system, so this is why MTDH is not essential for normal tissues.